Corcept Therapeutics Incorporated (CORT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CORT Revenue Growth
CORT Revenue Analysis (2014–2025)
As of May 8, 2026, Corcept Therapeutics Incorporated (CORT) generated trailing twelve-month (TTM) revenue of $769.1 million, reflecting modest growth of +4.9% year-over-year. The most recent quarter (Q1 2026) recorded $164.9 million in revenue, down 18.4% sequentially.
Looking at the longer-term picture, CORT's 5-year compound annual growth rate (CAGR) stands at +16.6%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $761.4 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including INVA (+13.6% YoY), HRMY (+20.7% YoY), and SUPN (+16.3% YoY), CORT has underperformed the peer group in terms of revenue growth. Compare CORT vs INVA →
CORT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CORTCurrent | $769M | +4.9% | +16.6% | 5.9% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 HRMY | $868M | +20.7% | +40.3% | 24.0% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% |
CORT Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $761.4M | +12.8% | $748.4M | 98.3% | $44.8M | 5.9% |
| 2024 | $675.0M | +39.9% | $664.2M | 98.4% | $137.0M | 20.3% |
| 2023 | $482.4M | +20.0% | $475.9M | 98.7% | $107.3M | 22.2% |
| 2022 | $401.9M | +9.8% | $396.5M | 98.7% | $112.6M | 28.0% |
| 2021 | $366.0M | +3.4% | $360.7M | 98.6% | $124.5M | 34.0% |
| 2020 | $353.9M | +15.5% | $348.3M | 98.4% | $128.2M | 36.2% |
| 2019 | $306.5M | +22.0% | $301.0M | 98.2% | $111.6M | 36.4% |
| 2018 | $251.2M | +57.8% | $246.0M | 97.9% | $89.5M | 35.6% |
| 2017 | $159.2M | +95.8% | $155.6M | 97.8% | $52.9M | 33.2% |
| 2016 | $81.3M | +61.7% | $79.3M | 97.5% | $10.2M | 12.5% |
See CORT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CORT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CORT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCORT — Frequently Asked Questions
Quick answers to the most common questions about buying CORT stock.
Is CORT's revenue growth accelerating or slowing?
CORT revenue growth slowed to +4.9%, below the 5-year CAGR of +16.6%. TTM revenue is $769M. The deceleration marks a shift from historical growth rates.
What is CORT's long-term revenue growth rate?
Corcept Therapeutics Incorporated's 5-year revenue CAGR of +16.6% reflects the variable expansion pattern. Current YoY growth of +4.9% is near this long-term average.
How is CORT's revenue distributed by segment?
CORT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.